Podcast appearances and mentions of jason karlawish

Grant funding by the National Science Foundation has been cut by more than half this year, bringing the foundation's science funding to its lowest level in decades. Katrina Miller, who covers science for the New York Times, joins Host Flora Lichtman to unpack the cutbacks and discuss where the funding changes might lead.And, the FDA has cleared a blood test to help diagnose Alzheimer's disease. The first-of-its-kind test measures the levels of amyloid and tau proteins in a patient's blood, two major biomarkers of the disease. Alzheimer's researcher Jason Karlawish joins Flora to explain this new diagnostic tool and what it means for patients.Guests:Katrina Miller is a science reporter for The New York Times based in Chicago.Dr. Jason Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania's Perelman School of Medicine, and co-director of the Penn Memory Center, based in Philadelphia, Pennsylvania.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Have any of you watched the movie “The Notebook”?  At the end, one of the characters, who has dementia, experiences an episode of lucidity.  When I watched it, between tears (I'm a complete softie) I remember thinking, “Oh no! This will give people false hope!  That their loved one is ‘in there.' If only they could find the right key to unlock the lock and let them out.” Today we talk about lucid episodes and what they might mean to the person with dementia, their family and loved ones, to philosophers, to clinicians, to neuroscientists. Our guests are Andrea Gilmore-Bykovskyi, a nurse researcher, and Andrew Peterson, a philosopher. We had a wide ranging discussion that touched on (among many things): A consensus definition developed at an NIH conference, organized by the recently retired NIA program officer Basil Eldadah (we will miss you Basil!). Andrew complicates this definition, stating is raises more questions than answers. Hospice nurses know that terminal lucidity “is a thing” and have pretty much all  seen it Family and caregiver stories of lucid episodes and what they meant to them, including early glimpses into a study Andrea is doing using video to capture episodes and show them to family. Potential for experiences to elicit “false hope”, misunderstanding/misinterpreting, and changing say code status from DNR to full code (rare but happens). Sam Parnia's work on brain activity during CPR and near death episodes Ethical issues these lucid episodes raise  Should clinicians treat people with dementia as always lucid? Having some level of awareness?  Parallels between how we treat people with advanced dementia, who may or may not be lucid, and how we treat AI, who may or may not be conscious, or experiencing paradoxical lucidity on their way to full consciousness.  I try to say please and thank you to the AI I interact with other than Alexa, who is obviously way behind. The Age of Aging podcast episode on lucidity, featuring Anne Bastings, Jason Karlawish, Elizabeth Donnarumma, and Justin Clapp Was Andrew's song choice, “I can see clearly now” better than Eric's suggestion “Silent Lucidity” by Queensryche?   Enjoy! -Alex Smith  

All Home Care Matters and our host, Lance A. Slatton were honored to welcome back Dr. Jason Karlawish.   About Dr. Jason Karlawish:   Dr. Jason Karlawish is a physician, writer, and professor at the University of Pennsylvania. He researches bioethics, aging, and neuroscience and co-directs the Penn Memory Center, where he cares for patients.   He is the author of The Problem of Alzheimer's and Open Wound and has written for The New York Times, The Wall Street Journal, The Washington Post, and more. He serves on the boards of The Greenwall Foundation and Play On! Philly. He lives in Philadelphia.

Dr. K speaks with Alzheimer's expert Jason Karlawish, MD, about the new anti-amyloid Alzheimer's medications lecanemab (Leqembi) and donanemab (Kisunla). They discuss how biomarkers have changed diagnosing Alzheimer's disease, how well these new drugs work, and much more.

In conversation with Dr. Jason Karlawish In partnership with the Philadelphia Chamber Music Society The clinical consulting director of support groups at The CaringKind (formerly The Alzheimer's Association), Dasha Kiper has an MA in clinical psychology from Columbia University. For the past decade she has worked with dementia patients, counseled caregivers, led support groups, trained and supervised mental health professionals, and counseled former caregivers who now lead support groups. Informed by her work as both a counselor and work as a caregiver herself, Travelers to Unimaginable Lands employs a wide range of compassionate stories to combat the myth of the so-called perfect caregiver. These ''moving and often surprising'' (The Wall Street Journal) case histories meld science and storytelling to show that caregivers don't just witness cognitive decline in their loved ones with dementia-they are its invisible victims. Dr. Jason Karlawish is the author of The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It. A Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania, he is Co-Director of the Penn Memory Center, where he cares for patients. He also serves on the board of directors for The Greenwall Foundation, a grant-based organization dedicated to expanding bioethics knowledge. His essays have appeared in The New York Times, the Los Angeles Times, Forbes, and The Philadelphia Inquirer, among other places. Because you love Author Events, please make a donation to keep our podcasts free for everyone. THANK YOU! (recorded 4/30/2024)

In the past few years pharmaceutical companies have developed a string of new Alzheimer's drugs called anti-amyloids, which target amyloid plaques in patients' brains. These plaques are one of the key biomarkers of the disease.The first of these drugs, Aduhelm, was approved by the FDA in 2021 amid enormous controversy. The FDA approved the drug despite little evidence that it actually slowed cognitive decline in patients. Biogen, the maker of Aduhelm, pulled the plug on further research or sales of the drug last month.In January 2023 The FDA approved another anti-amyloid medication from Biogen, lecanemab, sold under the brand name Leqembi. This time, there was much stronger evidence. Clinical trial results showed that the drug showed a modest improvement in cognitive decline in the early phases of the disease. But the drug comes with risks, including brain swelling and bleeding.Most recently, at the beginning of March, the FDA delayed approval of another anti-amyloid drug, donanemab, created by Eli Lilly. The FDA said it will be conducting an additional review to further scrutinize the study design and efficacy data.From the outside looking in, these Alzheimer's drugs appear to be mired in controversy. How well do they actually work? And why has there been so much back and forth with the FDA?To answer those questions and more, guest host Arielle Duhaime-Ross talks with Dr. Jason Karlawish, professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania's Perelman School of Medicine, and co-director of the Penn Memory Center.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

What does it mean to live a good life when the very essence of your memory and autonomy begins to fade? In a world where aging is inevitable, the challenges of neurodegenerative diseases like Alzheimer's pose profound questions about identity, care, and dignity. Today, I'm honored to have a conversation with Dr. Jason Karlawish. He is the author of The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It. As a professor of medicine, medical ethics, health policy, and neurology at the University of Pennsylvania's Perelman School of Medicine, Dr. Karlawish's work transcends the traditional boundaries of science and ethics, offering new perspectives on how we care for those living with Alzheimer's and other forms of dementia. His journey has led him to pivotal roles at the Alzheimer's Disease Research Center and the Penn Memory Center, where he provides leadership in the Penn Program on Precision Medicine for the Brain (P3MB). He addresses the ethical challenges of aging brains and explores how diseases like Alzheimer's and Lewy body disease affect autonomy and self-determination through innovative projects. Dr. Karlawish is reshaping how we understand and support the Alzheimer's community. His essays on ethics and aging have appeared in publications such as The Hill, The New York Times, The Philadelphia Inquirer, STAT News, The Washington Post, and more. In our conversation today, we discuss the evolution of Alzheimer's from a misunderstood condition to a widely recognized crisis, the vital role of caregivers, and the transformative impact of storytelling and advocacy in changing the narrative of dementia care. Dr. Karlawish's insights not only highlight the complexities of Alzheimer's disease but also celebrate the human spirit's resilience. Join us as we discuss the journey of caregiving, the challenges and opportunities in research and policy, and how we can collectively foster a society that supports all aspects of aging with grace and dignity. Thank you, Dr. Karlawish, for your compassionate care, for infusing humanity into your practice, and for engaging in this meaningful conversation with me. I am grateful for your dedication and advocacy. Thank you! Learn more at www.jasonkarlawish.com   We are not medical professionals and are not providing any medical advice. If you have any medical questions, we recommend that you talk with a medical professional of your choice. willGather has taken care in selecting its speakers but the opinions of our speakers are theirs alone. Thank you for your continued interest in our podcasts. Please follow for updates, rate & review! For more information about our guest, podcast & sponsorship opportunities, visit www.willgatherpodcast.com

There is a growing push to change how we define Alzheimer's disease from what was historically a clinically defined syndrome to a newer biological definition based on the presence of positive amyloid biomarkers. This proposed new definition, championed by the Alzheimer's Association (AA) and the National Institute on Aging (NIA), proposes that the disease exists when the earliest manifestation of Alzheimer's pathophysiology can be detected (amyloid), even though onset of symptoms may be years in the future. On today's podcast we talk about the benefits and drawbacks of redefining Alzheimers to a biological definition with three experts in the disease: Heather Whitson, Jason Karlawish, and Lon Schneider. In particular we spend a good deal of time talking about what this means for asymptomatic patients who may have an abnormal biomarker, which by the proposed new definition would mean they would now have Alzheimer's disease.  If you are interested in learning more about the draft guidelines and the response from AGS to these guidelines, check out the following links: Revised Criteria for Diagnosis and Staging of Alzheimer's Disease: Alzheimer's Association Workgroup  AGS's response to the revised criteria  

In this podcast, Dr Williams continues the discussion with Dr Jason Karlawish of the Penn Memory Center with a deep dive into the Alzheimer's Disease diagnosis and emerging therapies.

In this podcast, Dr. Williams speaks with Dr. Jason Karlawish, Co-director of the Penn Memory Center and national expert on neurodegenerative diseases, about the evaluation and diagnosis of cognitive impairment, highlighting the various dementia subtypes and how to distinguish between them.

Concerned about your aging loved ones?In today's episode, hear about the remarkable ongoing research in Alzheimer's Disease, including advances in diagnosis and treatment. Every year there are more options to slow memory loss and prolong meaningful life, bringing hope to individuals around the world. Join Jennifer Reid, MD as she interviews Jason Karlawish, MD, a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania Perelman School of Medicine. He is co-associate director of the Alzheimer's Disease Research Center and co-director of the Penn Memory Center. He also directs the Penn Program on Precision Medicine for the Brain, which examines the bioethics of aging with a focus on diseases of the brain such as Alzheimer's disease and Lewy body disease.  A writer, Dr. Karlawish is also committed to translating science into society. His most recent book is titled, The Problem of Alzheimer's: How Science, Culture and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It.References from Episode:Penn Memory Center https://pennmemorycenter.org/Sites for Additional Resources:Eldercare Locator https://eldercare.acl.govNational Adult Day Services Association (www.nadsa.org)Seeking a mental health provider? Try Psychology TodayNational Suicide Prevention Lifeline: 1-800-273-8255SAMHSA's National Helpline - 1-800-662-HELP (4357)Dial 988 for Mental Health EmergencyThank you to Brendan Callahan for the original music featured on the podcast.Disclaimer:The information and other content provided on this podcast or in any linked materials, are not intended and should not be construed as medical advice, nor is the information a substitute for professional medical expertise or treatment. All content, including text, graphics, images and information, contained on or available through this website is for general information purposes only.If you or any other person has a medical concern, you should consult with your health care provider or seek other professional medical treatment. Never disregard professional medical advice or delay in seeking it because of something that have read on this website, blog or in any linked materials. If you think you may have a medical emergency, call your doctor or emergency services (911) immediately. You can also access the National Suicide Help Line at 1-800-273-8255  The Reflective DocWebsite - Instagram - Facebook - Linked In - Twitter - Think Like a Shrink Blog on Psychology Today

It's been over two years since one of the worst product launches of all time - Aduhelm (aducanumab).  Praised by the FDA, Alzheimer's Association (AA), and Pharma as a “game changer”, but derided by others for the drug's lack of clinical efficacy, risk of severe adverse effects, absence of diversity in trial populations, high costs, and an FDA approval process that was in the kindest words “rife with irregularities”. Instead of Biogen's expected billions of dollars of revenue from Aduhelm, they brought in only $3 million in revenue for all of 2021 (here is my Twitter summary of this fiasco). The outlook on amyloid antibodies are looking brighter though in 2023.  Phase III studies for lecanemab and donanemab have been published showing less worsening of cognition and function receiving these agents versus placebo. This led the FDA to give full approval for lecanemab, which will likely be followed by full approval of donanemab sometime this year. However, as noted in our editorial published with the donanemab trial, the modest benefits of amyloid antibodies would likely not be questioned by patients, clinicians, or payers if amyloid antibodies were low risk, inexpensive, and simple to administer.  However, they are none of these.  So what is the role of individuals like geriatricians in prescribing amyloid antibodies and caring for individuals who are receiving them?  We invited three geriatricians and memory care doctors, Nate Chin, Sharon Brangman, and Jason Karlawish, to talk about this question and many others swirling around on how to safely prescribe these drugs and manage patients on them (like what to do about anticoagulation). Lastly, we also spend a little bit of time talking about the NIA-AA draft statement on redefining Alzhiemers disease.  There is a lot to digest with these draft clinical guidelines but the big change from the 2018 guideline is moving Alzheimers to a biological diagnosis (biomarker evidence only) not just for a research framework but now from a clinical one.  One outcome would be a very large population of older adults with normal cognition could now be classified as having Alzheimer's disease (maybe about a 1/3 of cognitively normal 75 year olds based on PET). So if you have thoughts on the matter, please give your feedback here to the NIA and AA. https://aaic.alz.org/nia-aa.asp By: Eric Widera

Physician and professor Jason Karlawish argues that new promising drugs like lecanemab, an anti-amyloid antibody expected to be approved by the FDA July 6, will introduce complicated issues into the field of Alzheimer's care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

We've talked at length on prior podcasts about the failures of aducnumab, Biogen, and the FDA's decision to approve it.   But wait, there's a shiny new anti-amyloid drug, lecanemab!  (No it's not just the French version of Aducanumab).   In an article in the NEJM (a published article this time, wonder of wonders!) lecanemab was shown to slow the rate of cognitive decline by 0.45 points on an 18 point cognitive scale compared to placebo.  Wow!  Wow?  Wait, what?   On today's podcast we talk with Jason Karlawish, who we've had on previously talking about his book The Problem of Alzheimer's and with Aaron Kesselhim, to discuss FDA approval of Aducanumab, as well as frequent guest and host Ken Covinsky.   They debate today's central question: is it time for geriatricians to get on board with lecanemab?  Along the way we address: Is this degree of slowed cognitive decline meaningful to patients or care partners? What about the burdens, risks, and harms? Every 2 week visits for infusions, regular monitoring for brain swelling and bleeding, case report level risk of death? Did the study do enough to address issues of inclusion and diversity by age, race and ethnicity, and multimorbidity? What does this study say about the amyloid hypothesis? Should the FDA approve, and under what conditions? Their answers may surprise you.   As a preview of final thoughts at the end of the episode, Ken and Jason agree that the FDA should approve lecanemab conditional on a post-approval monitoring system and public access to study data, geriatricians should be prepared to have thoughtful conversations with patients about the risks and benefits of lecanemab in view of their values and priorities, and ultimately, that geriatricians should be open to prescribing it.  Wow! The times, they are a changin. -@AlexSmithMD 

All Home Care Matters was honored to welcome a remarkable and distinguished guest to the show, Dr. Jason Karlawish.   Dr. Karlawish is a physician, writer, and author.   He researches and writes about issues at the intersections of bioethics, aging, and the neurosciences. He is the author of The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It and the novel Open Wound: The Tragic Obsession of Dr. William Beaumont.   Dr. Karlawish has also written essays for the Los Angeles Times, The New York Times, The Washington Post, Forbes, The Hill, Nature, STAT, and the Philadelphia Inquirer.   Currently he is a Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania and Co-Director of the Penn Memory Center, where he cares for patients. He is a member of the Board of Directors of The Greenwall Foundation. He lives in Philadelphia.

Though several validated biomarkers are studied and used in Alzheimer's disease research, most research participants don't have the opportunity to learn their biomarker results afterward, even if they have cognitive impairment. Drs. Jason Karlawish and Josh Grill join the podcast to discuss the debate over sharing biomarker results with research participants, how these powerful disclosures can be made ethically, and why it's as important for the field to study biomarker disclosures as it is to study the biomarkers themselves. Guests: Josh Grill, PhD, director, Institute for Memory Impairments and Neurological Disorders, associate professor, University of California, Irvine, and Jason Karlawish, PhD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania Show Notes Read Dr. Jason Karlawish and Dr. Josh Grill's viewpoint piece, “Disclosing Alzheimer Disease Biomarker Results to Research Participants,” from JAMA Neurology's June 2022 issue. Listen to our episode with Dr. Daniel Gibbs about his book (mentioned by Dr. Karlawish at 34:21) on our website, Spotify, Apple Podcasts, or wherever you listen. Listen to our past episode on amyloid disclosures with research participants on our website, Spotify, Apple Podcasts, or wherever you listen. Learn more about Dr. Josh Grill at his bio on the University of California - Irvine website. Learn more about Dr. Jason Karlawish's work at his website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter.

Dr. Jason Karlawish (the University of Pennsylvania) is the author of "The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What we can do about it. " Dr. Karlawish gives a presentation of the same name at the University of Wisconsin-Parkside on Wednesday morning, October 12th, at 9 a.m. More information about this free event and how to register for it is available at uwp.edu/hhs.

The June 2022 replay of past episodes showcases a selection of interviews about the impact of the FDA's approval of aducanumab for the treatment of Alzheimer disease (AD). This episode features illuminating conversations with Drs. Gregg Day, Ron Petersen, and Jason Karlawish on the clinical science guiding amyloid-based treatments for AD, the importance of patient participation when considering the use of aducanumab, and the business of Alzheimer disease, respectively. This month's Recall concludes with an interview featuring Pulitzer Prize-winning journalist Pam Belluck on Medicare's limitations on aducanumab coverage.

Alzheimer's disease affects millions of people and their families. Scientists have made extraordinary progress characterizing the pathology of Alzheimer's and working to find effective treatments. As scientists continue to unlock more and more about the disease and how to combat it, how can we address the challenges currently facing doctors, patients, and caregivers? In this 360 Perspective episode, we talk about the history of Alzheimer's, the stigma surrounding it, disparities in healthcare, and the impacts on caregivers. We interviewed Drs. Carl Hill, Stephanie Kalb, Jason Karlawish, Gad Marshall, and Stephen Salloway to discuss these issues. Music credits: Myuu - “Suspicious” Sneaky Snitch Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 License Additional music provided by Aaron Troutman.

Jason Karlawish is a geriatrician, a writer, a professor of medicine, medical ethics and health policy and neurology at the University of Pennsylvania, and is co director of the Penn Memory Center where he cares for patients. I couldn't wait to speak to Dr. Karlawish about his compelling and eye opening new book, The Problem of Alzheimer's How Science, Culture and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It. It answered so many of my questions regarding research, policy and how we got here.

Amid the gradual aging of the American population, there's never been more awareness about Alzheimer's and other dementias – but the stigmas and misconceptions have also persisted alongside this public knowledge, even among well-meaning people. At the University of Pennsylvania's Penn Memory Center, Dr. Jason Karlawish and his colleagues take a holistic approach to caring for people living with Alzheimer's and other forms of dementia; as a medical ethicist and author, he also probes the ways that society devalues caregiving as a vital role, while also treating elders with cognitive decline as “others.” Karlawish joins Susan Ryan for a provocative discussion about Alzheimer's and dementia not just as diseases, but as social constructs: Why was losing one's sense of agency and self-reliance considered a natural part of aging, and not a disease, until relatively recently in human history? Why do we view family caregivers as housekeepers or visitors instead of crucial supports who can help people with dementia live more fulfilling lives – the way wheelchairs and other mobility aids allow those with physical disabilities to navigate the world more freely? The answers to those questions will only become more vital as policymakers continue to debate eldercare reforms – and as new generations of both familial and professional caregivers look to improve the lives of America's elders.    Learn about the Penn Memory Center and its philosophy on care: https://pennmemorycenter.org/who-we-are/ Read about Karlawish's recent book, “The Problem of Alzheimer's”: https://www.publishersweekly.com/978-1-250-21873-5 Show notes/call to action: Learn more about The Green House Project: www.thegreenhouseproject.org

On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer's disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer's disease treatments in the future. Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania Episode Topics 1:48 What's the difference between the FDA and Centers for Medicare and Medicaid Services? 3:58 What is the purpose of sharing a proposal and allowing public comment after? Is it possible the proposal could change? 9:09 What are your key takeaways from the CMS proposal? 11:58 Who's being charged the cost of the treatment if it is part of a clinical trial? 18:33 What does this decision, with its focus on research often occurring in major urban medical centers, mean for equity and access? 26:27 What is the future of Alzheimer's disease research after the CMS decision? Show Notes Read the Center for Medicare and Medicaid Services's press release about the proposed coverage policy, view submitted public comments about the decision, and submit your own comment. Learn more about Dr. Jason Karlawish's work and writing at his website. Listen to our four-part episode series with Dr. Jason Karlawish about his book, The Problem of Alzheimer's, on our website (episode 1, episode 2, episode 3, episode 4).

In this episode, Karishma interviews Dr. Jason Karlawish, Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania Perelman School of Medicine. We discuss the bioethics of aging and Alzheimer's as well as the recent controversial FDA approval of aducanumab to help treat Alzheimer's disease. We explore issues from the implications of aducanumab's approval on care and treatment of patients with Alzheimer's, how it will impact prescribing habits, and the shared decision-making process between providers and the patient and their caregivers.

Dr. Jason Karlawish, author and Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania and Co-Director of the Penn Memory Center, talks with Caregiver SOS on Air cohosts Carol Zernial, nationally known expert on gerontology, and veteran broadcaster and attorney Ron Aaron about Dr. Karlawish's book - "The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis." For more visit www.jasonkarlawish.com. See omnystudio.com/listener for privacy information.

Aducanumab is a new drug designed to remove amyloid in the brain. Following an accelerated process, the Food and Drug Administration approved Aducanumab as a treatment for Alzheimer's disease despite (what many experts feel) little evidence of effectiveness. In this episode we discuss the approval of Aducanumab with Dr. Jason Karlawish from the University of Pennsylvania and talk about what it could mean for drug discovery going forward. The transcript for this episode can be found here. Related Links: CAPRA Website: http://capra.med.umich.edu/ The Problem of Alzheimer's by Jason Karlawish: https://us.macmillan.com/books/9781250218742 Jason Karlawish Website: jasonkarlawish.com FDA Aducanumab Approval Press Release (June 2021): https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug You can subscribe to Minding Memory on Apple Podcasts, Spotify, Google Podcasts or wherever you listen to podcasts. Hosted on Acast. See acast.com/privacy for more information.

Alzheimer's disease used to be a rare diagnosis. But today, more than 5.8 million Americans are living with Alzheimer's and this number is projected to triple to 14 million over the next forty years. In this episode, Emily discusses the mounting practical, moral, and ethical quandaries of caring for patients with Alzheimer's and other dementia-causing diseases with Dr. Jason Karlawish, author of The Problem of Alzheimer's: How Science, Culture and Politics Turned a Rare Disease into a Crisis and What We Can Do About It. The Nocturnists are partnering with VCU Health Continuing Education to offer FREE CME credits for healthcare professionals. Visit ce.vcuhealth.org/nocturnists to claim credit for this episode. More at thenocturnists.com.

In the first part of the podcast, Dr. Jason Crowell discusses the business of Alzheimer disease and how to approach teaching patients about aducanumab with Dr. Jason Karlawish. In the second segment, Dr. Jennifer Bickel talks with Dr. Eric Kaiser about the contribution of melanopsin and cone signals to light-induced reflexive eye closure in migraine.

Dr. Jason Crowell discusses the business of Alzheimer's disease and how to approach teaching patients about aducanumab with Dr. Jason Karlawish.

The FDA label for the amyloid antibody aducanumab (Aduhelm) started off exceedingly broad, basically including anyone with Alzheimer's disease, but was subsequently narrowed to to patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD).  Should, though, the label be even more restrictive to mirror the populations studied in the two still unpublished trials of the drug, EMERGE and ENGAGE?  Or should CMS consider restricting coverage for aducanumab to populations meeting trial eligibility criteria and requiring additional evidence on clinical outcomes in groups excluded from the trials? In today's podcast, we talk with Tim Anderson and Marco Canevelli, the authors of two recent articles published about the real world eligibility of aducanumab: Tim Anderson was first author of a JAMA research letter that found that more than 92% of Medicare beneficiaries with Alzheimer's Dementia and 85% of those with MCI would have been excluded in the clinical trials of aducanumab based on their age or comorbid conditions.  Marco was first author of a JAGS letter to the editor that systematically applied the EMERGE and ENGAGE exclusions to 911 patients with cognitive complaints who went to A geriatric outpatient unit in Milan (Italy). Only six patients (i.e., 0.66%) of these patients would potentially be candidates to aducanumab. For more podcasts on aducanumab, check out these two: All things Amyloid, including Aducanumab and Amyloid PET scans with Gil Rabinovici Aducanumab (Aduhelm) for the Treatment of Alzheimers: A Podcast with Aaron Kesselheim and Jason Karlawish

Dr. Jason Karlawish, physician and professor at the University of Pennsylvania and co-director of the Penn Memory Center, speaks with us about his book, "The Problem of Alzheimer's: How Science, Culture and Politics Turned a Rare Disease into a Crisis." The discussion was insightful in many ways. We talked about how Alzheimer's was first identifed as a disease, rather than just an outcome of aging. The challenges facing caregivers and the cost of long-term care, on individuals, families and society. We looked at how politics has used rhetoric to design a health care system that is not focused on long-term care or the expansion of a social insurance program. And we talked about some of the moral and ethical questions that caregivers face, such as "loving deception." The book shares stories of patients of Dr. Karlawish, he gets into the history of the scientists that first identified Alzheimer's as a disease and how the World Wars stopped the research and innovation. It is a valuable read and I would highly recommend it. You can subscribe to all Hey, Boomer materials on our website: https://heyboomer.biz  You can reach Dr. Karlawish through his website: www.jasonkarlawish.com  makingsenseof alzheimers.org is the other website mentioned in this episode

Dr. Jason Karlawish, author and Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania and Co-Director of the Penn Memory Center, talks with Caregiver SOS on Air cohosts Carol Zernial, nationally known expert on gerontology, and veteran broadcaster and attorney Ron Aaron about Dr. Karlawish's book - "The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis." For more visit www.jasonkarlawish.com.

Dr. Jason Karlawish, author and Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania and Co-Director of the Penn Memory Center, talks with Caregiver SOS on Air cohosts Carol Zernial, nationally known expert on gerontology, and veteran broadcaster and attorney Ron Aaron about Dr. Karlawish's book - "The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis." For more visit www.jasonkarlawish.com. See omnystudio.com/listener for privacy information.

Patti welcomes Dr. Jason Karlawish, co-director of the Penn Memory Center, and author of “The Problem of Alzheimer's – How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It”.  They define the difference between mild cognitive impairment, dementia, and Alzheimer's and address the stigma associated with this disease.  America is one of the few western global democracies that has not formulated a national healthcare plan to cover the rising costs associated with caring for individuals suffering from this disease.  Dr. Karlawish identifies the signs to look for in diagnosing this disease and reveals how recent biomedical breakthroughs can spur our healthcare system from failing these patients to saving them.

In this session Danielle Kelly, our Director of Culture & Inclusion at Herbert Smith Freehills joins leading expert on Dementia Dr Jason Karlawish for an important and enlightening conversation on dementia and Alzheimers.During this session Dr Karlawish breaks the disease down for us by exploring the types of Dementia, the role of a caregiver, the early signs of Dementia, the typical stages of Dementia and the medical tests used for dementia diagnosis. For local resources in Australia, Dementia Australia represents the over 450,000 Australians living with dementia and the almost 1.6 million Australians involved in their care. Visit Dementia Australia website: www.dementia.org.au

As we learn more and more about the brain, researchers are developing new neuroscientific methods that can help diagnose patients with traumatic brain injury. For example, some of these methods might even be able to tell us that patients who otherwise appear unresponsive are actually still "alive inside". That's an amazing idea, but the story doesn't stop there. As such technology develops, it raises a number of ethical questions about how it works and how to use. In this paper, Andrew and his coauthors investigate the benefits, harms, and costs of using neuroimaging to detect human consciousness. Links and Resources * Andrew Peterson (https://philosophy.gmu.edu/people/apeter31) * The paper (https://onlinelibrary.wiley.com/doi/full/10.1111/bioe.12678) * Experiences of family of individuals in a locked in, minimally conscious state, or vegetative state with the health care system (https://bmcmedethics.biomedcentral.com/articles/10.1186/s12910-021-00674-8) * Ethical issues in neuroimaging after serious brain injury with Charles Weijer (https://www.charlesweijer.com/neuroimaging-project) * Practice guideline update recommendations summary: Disorders of consciousness (https://n.neurology.org/content/91/10/450) * Jason Karlawish (https://www.med.upenn.edu/apps/faculty/index.php/g275/p7909) * Adrian Owen (https://owenlab.uwo.ca/) Paper Quotes The practice guideline update is a milestone in the history of neurology. Recommendations to use investigational neuroimaging methods are but one aspect of the guideline, and there is a need for further normative analysis of its rich content. We encourage continued debate on these issues. Bringing clarity to the underlying ethics of caring for brain‐injured patients can assist clinicians and health care institutions as they incorporate the guideline in clinical practice. We think that investigational neuroimaging could facilitate access to opportunity for DoC patients. As the guideline highlights, investigational neuroimaging could function as a gatekeeper for continued rehabilitation, and it might also be used as a neural prosthetic, based on future technical improvements. Neuroimaging assessment could also inform clinical decisions that best reflect a patient's values, even if pursuing those values are inconsistent with standard notions of quality of life. Opportunity‐based frameworks for healthcare justice still require conceptual refinement, and further work needs to be done to thoroughly apply such a framework to the DoC context. However, we believe that this is a promising avenue of future research to explicate the justice claims that DoC patients (or other disabled populations) have to investigational neuroimaging and other novel therapies. Special Guest: Andrew Peterson.

After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog. Aaron Kesselheim, a Harvard Medical School professor, served on the FDA's advisory committee that considered Aduhelm and voted against its approval. He explains why he decided to resign from his post and what consequences there could be for future research and also for Medicare and Medicaid for covering such an expensive drug. Geri Taylor has participated in the Aduhelm trial since 2015 and both her and her husband Jim believe that the drug has slowed her decline. Jason Karlawish - a practising physician, co-director of the Penn Memory Centre and the author of The Problem of Alzheimer's book - says that more money should be spent on providing carers for the vast majority of Alzheimer's patients and that people should not be forced to choose between cure and care. PHOTO: 3d illustration of the human brain with Alzheimer's disease/Getty Images

In this session Danielle Kelly, our Director of Culture & Inclusion at Herbert Smith Freehills joins leading expert on Dementia Dr Jason Karlawish for an important and enlightening conversation on dementia and Alzheimers. During this session Dr Karlawish breaks the disease down for us by exploring the types of Dementia, the role of a caregiver, the early signs of Dementia, the typical stages of Dementia and the medical tests used for dementia diagnosis. For local resources in Australia, Dementia Australia represents the over 450,000 Australians living with dementia and the almost 1.6 million Australians involved in their care. Visit Dementia Australia website: www.dementia.org.au

Aducanumab has been a hot topic in the field of dementia and Alzheimer's disease. Aducanumab, also known as Aduhelm, is a new Alzheimer's drug for people with Alzheimer's disease in their early stages with mild cognitive impairment. With so many questions, it helps to have answers from experts like Dr. Jason Karlawish, Neurologist and Co-Director of the Penn Memory Center.In this episode, Dr. Karlawish and I discucss:Reasons that Dr. Karlawish is a "reluctant prescriber" of AducanumabThe risks and benefits of Aducanumab for Alzheimer's DiseaseHow the FDA made the decision to approve Aducanumab for useThe answer to the question: "is some hope is better than no hope?" (related to the use of Aducanumab for Alzheimers.)The effects of the COVID-19 virus on brain health (i.e., risk for dementia)The difference between FDA approval for Aducanumab versus COVID-19 vaccineClick here to visit the show notes page for all the resources mentioned in today's episode:Older Adult / Family? Download the Memory Loss & Mental Health GuideProfessional? Grab the Mental Health Professional's Guide to Working with Older AdultsHelp others find this show by subscribing and leaving a review wherever you listen to the podcast, or here on i-tunes.--DISCLAIMER: The material on this site is for informational and educational purposes only. Any comments Dr. Koepp may make on the TV Show, blog, or in response to an individual's story or comments should not be construed as establishing a psychologist-patient relationship between Dr. Koepp and the individual. None of Dr. Koepp's show, website, social media, comments, or group information should be considered a substitute for individualized medical or mental health assessment, diagnosis, or treatment. Dr. Koepp is only representing herself in her TV Show, blogs, and on her website.Are you a licensed therapist, psychiatrist, or neuropsychologist who specializes with older adults? Join me in building the ONLY geriatric mental health provider directory in the nation. For a limited time, you can claim your profile here for FREE with the code: fullaccesspass (all lower case). Hurry! This offer is only valid for the first 100 profiles.

Alzheimer's is a Humanitarian Crisis. It Needs a Human Response. At Home With Growing Older is proud to be your host of At Home, On Air a bi-weekly radio hour offering connection, community and knowledge to our participants remotely. We invite you to listen and learn from this live recorded episode of, At Home, On Air with Anne Basting and Dr. Jason Karlawish. Learn more, donate today, and register for the next LIVE episode of At Home, On Air: www.athomewithgrowingolder.org

On June 7th, 2021 FDA approved the amyloid beta-directed antibody aducanumab (Aduhelm) for the Treatment of Alzheimers. This approval of aducanumab was not without controversy.   Actually, let me restate that.  The approval of aducanumab was a hot mess, inside a dumpster fire, inside a train wreck.  After the approval, three members of the FDA advisory panel, which unanimously was not in favor of the approval of aduhelm, quit.  One of them, Aaron Kesselheim (who we have on our podcast today) described it as “the worst drug approval decision in recent U.S. history" in his resignation letter. Then the FDA had to revise the label one month after publishing it because the original didn't even come close to looking like the population in which treatment was initiated in clinical trials.  Then, wait for it, after a firestorm of criticism the FDA's commissioner had to ask for an independent investigation to look into the interactions between Biogen representatives and FDA members.  And now CMS is deciding if and how to cover Aduhelm, a drug that will cost at least $56,000 a year per patient not incluiding the doctor's visits, amyloid PET scans, and frequent MRIs that will be necessary to monitor for side effects. On today's podcast we talk all about aducanumab with Aaron Kesselheim, Professor of Medicine at Harvard Medical School and previous member of that now famous FDA advisory committee, as well as Jason Karlawish, Professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania Perelman School of Medicine. I'd love to point you to the journal articles for the two phase III trials on aducanumab, but as of yet, they are unpublished (this should tell you a little about the faith Biogen has on its drug data), so I'll leave you with these resources instead: Our podcast with Gil Rabinovici on “All things Amyloid, including Aducanumab and Amyloid PET scans” AGS's preliminary advice on prescribing Aducanumab -  Jason Karlawish's book, The Problem of Alzheimer's, and the previous podcast that we did on it  FDA's document dump on Aduhelm  Biogen's open letter to the Alzheimer's disease community complaining about the “turn outside the boundaries of legitimate scientific deliberation” that has occurred with aduhelm (while ignoring the fact that the trials have not been published yet). CMS's request for public comment for their National Coverage Determination analysis to determine whether Medicare should cover the drug and any other monoclonal antibodies directed at amyloid The last one is particularly important as whether you are for or against the coverage of aducanumab, your voice matters. There is a letter being circulated by physicians who care for people with Alzheimer's Disease urging CMS not to cover aducanumab given the limited clinical evidence for benefit, known harms, and exorbitant cost. You can find the letter here.  If you would like to sign the letter, you can add your name by clicking this link.  

The pandemic had a high mortality toll in care homes, but measures to try and reduce that, through extreme social isolation, has had its own cost. Social interaction, particularly with close family, is more than just a quick hello - evidence shows that mental stimulation can help with cognitive decline, and the lack of that interaction may have hastened progression of dementia in some patients. In this podcast, the team talk about what GPs can do to support patients in care homes, and we find out about some non-drug interventions patients can try. Our guests; Jason Karlawish, is a geriatrician, and co-director of the Penn Memory Center, he's also author of the book "The Problem of Alzheimer's How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It" Jennifer Watt is a geriatrician, and assistant professor at the university of Toronto, and one of the authors of the recent systematic review and meta-analysis of comparative efficacy of interventions for reducing symptoms of depression in people with dementia - https://www.bmj.com/content/372/bmj.n532 Reading; Washington Post article: https://www.washingtonpost.com/health/2020/09/16/coronavirus-dementia-alzheimers-deaths/?arc404=true Jason Karlawish and his book https://www.jasonkarlawish.com/the-problem-of-alzheimers This American Life episode: https://www.thisamericanlife.org/737/the-daily The Daily episode on aducanumab, "some hope is better than having no hope" https://www.nytimes.com/2021/07/07/podcasts/the-daily/aduhelm-alzheimers-fda-drug.html

Dementia is a general term for loss of memory, language, problem-solving, and other thinking abilities that are severe enough to interfere with daily life. Alzheimer's is the most common cause of dementia.As life expectancies increase, more and more people are at risk of developing dementia. But what does it even mean?According to alz.org, in the United States, there are more deaths from Alzheimer's and dementia than from breast cancer and prostate cancer combined. In the past few years, Alzheimer's deaths have increased by 16%. In 2021, Alzheimer's will cost the nation $355 billion. By 2050, this number could be over $1 trillion. More than 11 million Americans take care of people with Alzheimer's or other dementias without getting paid for it.Join me and Dr. Jason Karlawish as we chat about how you need to prepared for the increase in cases of dementia. We talked about how often people are getting dementia. 100 years ago, people did not get it as much and the cases were not diagnosed. They were not dying from it as often. Now, there are more cases of Alzheimer's than before. What would you do if you went back in time and talked to someone with memory problems? If the person has problems early on in life, they can be diagnosed with Alzheimer's. To help them, we need policy changes that will improve the well-being and dignity of people living with dementia.--------------------Timestamps:[00:00] Pre-intro dialogue from Jason Karlawish[01:41] Friendly get to know you and Hanh's experience with dementia in her family.[04:05] Introduction to Jason Karlawish[04:46] Jason's background, including what exactly sparked his interest in Alzheimer's and Dementia?[06:06] It seems like a hundred years ago, people didn't die of Alzheimer's as often. Was it just underdiagnosis or something else?[09:36] If you could go back a hundred years, what would you do to educate people about Alzheimer's to prevent us from being in the place where we are today?[11:25] How are we able to diagnose Alzheimer's early, even before a person has any memory problems?[14:40] Things we can do now to prepare for the future increase in cases of dementia?[17:41] What effect does a negative stigma around memory loss and dementia have on those with dementia?[19:20] Ageism and its role in these stigmas?[19:38] What could we do to break down these stereotypes? On a personal level and cultural level?[23:42] Your thoughts on Biogen's new drug?[25:19] Why are some people confused about the moral aspects of Alzheimer's medication?[27:06] Thoughts on future success as an Alzheimer's medication?[28:45] Ways to improve Alzheimer's disease treatment today without using drugs like Biogen's, returning to old treatments, such as HRT or Donepezil?[31:45] Implications social media have for our sense of determination in a society?[33:02] Anything else that you would like to add?[34:49] Where can listeners find you and find your book?--------------------Bio:Dr. Jason Karlawish is a physician and writer who researches and writes about issues at the intersection of bioethics, aging, and the neurosciences. Dr. Karlawish's work has aired on NPR (National Public Radio) as well as The New York Times, Washington Post, Forbes, Philadelphia Inquirer, and many others. His book "The Problem of Alzheimer's" will be published February 2021 by Macmillan/St Martin's Press in association with TED Books; this book tells the story of how science culture politics turned a rare disease into a crisis that we can do something about!Find out more about Jason:LinkedIn: https://www.linkedin.com/in/jason-karlawish-a4888030/Website: https://www.jasonkarlawish.com/

In his new book The Problem of Alzheimer's, Dr. Jason Karlawish from the Penn Memory Center traces the history of a condition that impacts nearly 6 million Americans at a cost of more than $225 billion annually. These numbers may triple over the next decade. In today's episode, Dr. Karlawish discusses potential breakthroughs in the years ahead – both pharmacologic and social – that can help us weather this storm. We also review the FDA's controversial approval last week of aducanumab, the first new drug for Alzheimer's in nearly two decades.**Be sure to subscribe to The Healthy Skeptic MD on your favorite podcast app and on Youtube!Link for our channel on podcast apps and Youtube: wavve.link/healthyskepticmd

This week is a special two-part episode focusing on last week's controversial — some say inflammatory — decision to approve aducanumab, a new Alzheimer's drug. In these episodes, I talk with two Alzheimer's experts with vastly different viewpoints on the news. Second up: Jason Karlawish, an Alzheimer's physician who wrote a First Opinion in May about how he would not prescribe the drug, were it to be approved.

There's excitement — and controversy — surrounding Biogen's new Alzheimer's drug. What are doctors saying? Dr. Jason Karlawish and Dr. Gayatri Devi discuss the drug's promise and peril. And, ProPublica revealed a trove of tax records showing the megarich pay next to nothing in income taxes. Robert McClelland of the Urban-Brookings Tax Policy Center weighs in.

The U.S. Food and Drug Administration just approved Biogen's new Alzheimer's drug Aducanumab, a historic move as it is the first new therapy for the disease in nearly two decades. The drug will be marketed under the name Aduhelm and is expected to generate billions of dollars in revenue for Biogen. Dr. Jason Karlawish, co-director of the University of Pennsylvania Medical Center, discusses the new Alzheimer's drug, saying that the evidence to approve the drug “was not sufficient.” U.S. law enforcement officials said Monday they were able to recover $2.3 million in bitcoin paid to a criminal cybergroup involved in the crippling ransomware attack on Colonial Pipeline. NBC's Ken Dilanian reports the FBI won't reveal how it cracked the ransomware gang's bitcoin account. CNBC's Ylan Mui discusses the Senate's agenda, including assignments relating to the wage gap, voting rights and judicial nominations. The Senate is also set to pass an industrial policy bill to counter China. NBC's Kerry Sanders discusses Vice President Kamala Harris's visit to Guatemala as the Biden administration tries to stem the surge of migrants at the southern border. Plus, a secret VIP lounge located in New York City where you can customize your own Lamborghini car.

FDA approved the controversial Alzheimer's drug aducanumab. We'll talk with Penn Memory Center's Dr. Jason Karlawish about the decision and the state of Alzheimer's research.

In 2020, an estimated 5.8 million Americans had Alzheimer's, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It (St. Martin's Press, 2021) traces Alzheimer's from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems' failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer's to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers' support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. To discuss and propose the book for an interview you can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/neuroscience

In 2020, an estimated 5.8 million Americans had Alzheimer's, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It (St. Martin's Press, 2021) traces Alzheimer's from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems' failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer's to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers' support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. To discuss and propose the book for an interview you can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices

In 2020, an estimated 5.8 million Americans had Alzheimer's, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It (St. Martin's Press, 2021) traces Alzheimer's from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems' failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer's to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers' support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. To discuss and propose the book for an interview you can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/psychology

In 2020, an estimated 5.8 million Americans had Alzheimer’s, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It (St. Martin's Press, 2021) traces Alzheimer’s from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems’ failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer’s to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers’ support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. To discuss and propose the book for an interview you can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

In 2020, an estimated 5.8 million Americans had Alzheimer’s, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It (St. Martin's Press, 2021) traces Alzheimer’s from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems’ failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer’s to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers’ support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. To discuss and propose the book for an interview you can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science-technology-and-society

In 2020, an estimated 5.8 million Americans had Alzheimer's, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It (St. Martin's Press, 2021) traces Alzheimer's from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems' failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer's to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers' support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. To discuss and propose the book for an interview you can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

In 2020, an estimated 5.8 million Americans had Alzheimer’s, and more than half a million died because of the disease and its devastating complications. 16 million caregivers are responsible for paying as much as half of the $226 billion annual costs of their care. As more people live beyond their seventies and eighties, the number of patients will rise to an estimated 13.8 million by 2025. Part case studies, part meditation on the past, present and future of the disease, The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It (St. Martin's Press, 2021) traces Alzheimer’s from its beginnings to its recognition as a crisis. While it is an unambiguous account of decades of missed opportunities and our health care systems’ failures to take action, it tells the story of the biomedical breakthroughs that may allow Alzheimer’s to finally be prevented and treated by medicine and also presents an argument for how we can live with dementia: the ways patients can reclaim their autonomy and redefine their sense of self, how families can support their loved ones, and the innovative reforms we can make as a society that would give caregivers and patients better quality of life. Rich in science, history, and characters, The Problem of Alzheimer's takes us inside laboratories, patients' homes, caregivers’ support groups, progressive care communities, and Jason Karlawish's own practice at the Penn Memory Center. Galina Limorenko is a doctoral candidate in Neuroscience with a focus on biochemistry and molecular biology of neurodegenerative diseases at EPFL in Switzerland. To discuss and propose the book for an interview you can reach her at galina.limorenko@epfl.ch. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In this episode, we're picking up where we left off in episode 148: “I felt I had been harmed” with guest Jamie Tyrone.  Jamie is the author of Fighting for My Life: How to thrive in the shadow of Alzheimer's. She unexpectedly found out about her risk of developing Alzheimer's disease in the course of genetic testing for something else. As you can imagine, that had a significant impact on her life. More about that in a minute. Meanwhile, fast-forward to February 2021. Phil Gutis, who is our Assistant Sherpa on the show and was diagnosed with young onset Alzheimer's five years ago, landed us an interview with Dr Jason Karlawish, who is both Co-Director of the Penn Memory Center and part of Phil's neurology team.  Dr Karlawish came on the pod to discuss his new book The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It. That conversation, featured in episodes 146: “It's a disease of autonomy” and 147: Safe, Social, and Engaged covered a lot of ground, as the title of the book suggests it would. One of the most intriguing ideas in the book is of creating a new diagnosis called "pre-clinical Alzheimer's.” Being able to diagnose people with "pre-clinical Alzheimer's” means they wouldn't be showing any symptoms of the disease, but rather that they have genetic markers indicating they'll likely develop it within their lifetime. People could live with a diagnosis of "pre-clinical Alzheimer's” for 30, 40, 50 years prior to showing symptoms. Now, back to Jamie Tyrone. She's been living with the information she has a significantly high risk of developing Alzheimer's disease for 11 years now. So of course we wanted to hear her thoughts on this idea of a "pre-clinical Alzheimer's” diagnosis.  In this episode, Phil and I have a conversation with Jamie about the psychological impact of genetic testing and knowing you have a diagnosis, or are at a significantly higher chance of eventually getting the dreaded diagnosis. The conversation got more real and raw than any of us anticipated. Affiliate disclosure: As an Amazon Associate I earn a small commission from qualifying purchases, at no/zero/none/nada additional cost to you. If you've heard/read/seen something helpful on The Alzheimer's Podcast or the Dementia Sherpa blog or YouTube channel, purchasing through the links on this page is a way to show support---thank you!).

I have a tough, loving conversation about dementia and Alzheimer's with Jason Karlawish, physician, researcher, professor, clinician, and author of The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It. This heartbreakingly common diagnosis creates multiple patients — both the diagnosed and the caregivers. We talk about the difference between Alzheimer's and dementia, how we respond to a disease that diminishes our autonomy, and what we can do to take care of ourselves and each other. Learn more about your ad choices. Visit podcastchoices.com/adchoices

There has been "spectacular" progress in recent years in the understanding and treatment of Alzheimer's.  The progressive disease, which is the most common cause of dementia, a late-in-life decline in memory and cognitive ability, afflicts 50 million people around the world. Taking family members and other carers into account, that number increases exponentially.  The condition, for which there is currently no cure,  amounts to a modern day crisis, for all involved. In this episode of the LLAMA podcast, Dr Jason Karlawish, a gerontologist and professor of medicine and medical ethics and senior fellow of the Center for Bioethics at the University of Pennsylvania, says significant gains are being made with therapeutic treatments, but many hurdles remain.  The author of The Problem of Alzheimer's: How Science, Culture and Politics turned a Rare Disease into a Crisis, also argues that Alzheimer's is disease of our identity and a condition that raises fundamental, moral questions about what it means to lead a good life. Recorded: March 30, 2021 | Read a transcript and show notes at the LLAMA podcast website.Topics covered in this interview include:The difference between dementia and Alzheimer's disease.How can dementia be distinguished from the 'normal course of aging?"The work of the Penn Memory Center, with patients and their loved ones. Explaining medicine in the 'real world,' through the stories and experiences of people.Why patients and caregivers are the best teachers. Distinguishing between disease and disability. How stigma haunts the lives of people with dementia. Defining Alzheimers as once a rare disease, now a crisis. The "spectacular progress in science," dealing with Alzheimer's. "Living' with Alzheimer's rather than relying on drugs. Why is the risk of demential declining? The crisis of good quality care for Alzheimer's patients in the U.S.Regular exercise and a heart healthy diet to maintain good brain health.  Red wine too? This episode is brought to you in association with JUVICELL, the all-in-one longevity supplement that contains 10 key ingredients shown to have a positive impact on healthspan, as validated by scientific studies. To find out more, visit juvicell.comThe Live Long and Master Aging podcast, a HealthSpan Media LLC production, shares ideas but does not offer medical advice.  If you have health concerns of any kind, or you are considering adopting a new diet or exercise regime, you should consult your doctor.

We originally introduced you to our guest today, Jamie Tyrone, in episode 100: Enjoy Us in the Moment. In that episode, Jamie starts walking us through her experience of finding out (by accident!) she has two copies of the ApoE-4 gene, which puts her at a 91% lifetime risk of getting Alzheimer's disease. In addition to having a great-grandmother, grandmother, and two great-uncles who died of Alzheimer's disease, at the time Jamie found out her own genetic information, her dad was living with Alzheimer's disease. This is Jamie's third appearance on the show; episode 104: I Call it a Gift, is part two of the conversation we started in episode 100. We asked her back for a few reasons: number one, we wanted to hear Jamie's take on Dr. Jason Karlawish's idea about introducing a new diagnosis of "pre-clinical Alzheimer's," meaning people could theoretically be diagnosed decades before symptoms become apparent. (Dr. Karlawish talks about this in his new book The Problem of Alzheimer's and in episode 146: "It's a disease of autonomy" and episode 147: Safe, Social, and Engaged.)  As you can no doubt imagine, Jamie is in a position to speak authoritatively on what it's like to learn about and live with that information (which she discusses in detail in her book Fighting for My Life: How to Thrive in the Shadow of Alzheimer's.)   Number two, Jamie is a terrific storyteller---as you'll hear. And number three, Phil and I just adore her! :) This episode is part one of three in our latest conversation with Jamie.  Affiliate disclosure: As an Amazon Associate I earn a small commission from qualifying purchases, at no/zero/none/nada additional cost to you. If you've heard something helpful on The Alzheimer's Podcast, purchasing through these links is a way to show support---thank you!).

Jason Karlawish is a geriatrician, a writer, a professor of medicine, medical ethics and health policy and neurology at the University of Pennsylvania, and is co director of the Penn Memory Center where he cares for patients. I couldn't wait to speak to Dr. Karlawish about his compelling and eye opening new book, The Problem of Alzheimer's How Science, Culture and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It. It answered so many of my questions regarding research, policy and how we got here.

In this week's episode, Dr. Jason Karlawish and Richard Bartholomew, the husband and caretaker of one of his patients, share insight into the relationship between caregivers and clinicians when looking after someone with Alzheimer's. The conversation covers how diseases like Alzheimer's and Covid-19 ramify to affect more than just its patients, and how caregivers shouldn't be thought of as typical hospital visitors, but as essential members of the care team.

This episode is part two of our conversation with Dr. Jason Karlawish, author of the new book The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It. The book is out today (February 23, 2021) and is available as both an audio book on audiobooks.com, as well as hardback at your favorite bookseller. If you haven't yet listened to the first part of our conversation with Dr Karlawish in episode 146: It's a Disease of Autonomy, you'll want to hit pause and go back to that episode to catch up before coming back to this episode. Episode 146 explains the historical and political context that got us to where we are today and the way it influenced policy decisions around Alzheimer's disease. This episode focuses more on my main interest: the humans affected, and our relationship with them. Phil Gutis, former New York Times journalist and our Assistant Sherpa on The Alzheimer's Podcast, leads the conversation with Dr. Karlawish. Jason Karlawish is a physician and writer. He researches and writes about issues at the intersections of bioethics, aging, and the neurosciences. He is the author of the novel Open Wound: The Tragic Obsession of Dr. William Beaumont and his essays have appeared in The New York Times, The Washington Post, Forbes, and the Philadelphia Inquirer. He is a Professor of Medicine, Medical Ethics and Health Policy, and Neurology at the University of Pennsylvania and Co-Director of the Penn Memory Center, where he cares for patients. He lives in Philadelphia. Affiliate disclosure: As an Amazon Associate I earn a small commission from qualifying purchases, at no/zero/none/nada additional cost to you. If you've heard or read or seen something helpful on The Alzheimer's Podcast or the Dementia Sherpa blog or YouTube channel, purchasing through these links is a way to show support. Thank you!

Where are we with Alzheimers?  Are we about to see a revolution in how we diagnose and treat it with Amyloid PET scans and the amyloid antibody aducanumab (which is currently on FDA's desk for approval)?  Or are we still in the same place where there is no meaningfully effective treatment?  Or is it somewhere in between, given the data that we have on comprehensive dementia care? We talk today with Jason Karlawish, a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania Perelman School of Medicine. In addition to being a geriatrician extraordinaire, he is the author of the new book “The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It.” In addition to talking about PET scans and new drugs like aducanumab, we discuss with Jason about the history of Alzheimers, the history of how we care for a fund caregivers, and where we go from here. So take a listen and check out Jason's book!

Phil Gutis, former New York Times reporter and our Assistant Sherpa, interviews Dr. Jason Karlawish, author of the new book (available 2/23/21) The Problem of Alzheimer's: How Science, Culture, and Politics Turned a Rare Disease into a Crisis and What We Can Do About It. Dr. Karlawish was very generous with his time, so this episode is part one of two.  In part one, the wide-ranging conversation touches on: Aducanumab How we got to a place that -- 100+ years later -- still doesn't include a cure The concept of "pre-clinical Alzheimer's disease" Public stigma and self-stigma Why Dr. Karlawish believes there's reason to hope in the (relatively) near-term. Links to everything in the show notes at DementiaSherpa.com/episode146.

IMPACT Collaboratory PI Vince Mor speaks with Jason Karlawish, MD about his recent IMPACT Collaboratory Grand Rounds presentation on Modifications and Waivers of Informed Consent in Pragmatic Clinical Trials. Karlawish, Professor of Medicine, Medical Ethics and Health Policy, and Neurology, and Co-Director of the Penn Memory Center at University of Pennsylvania, focuses his research on issues at the intersections of bioethics, aging and the neurosciences.